Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001208493
Ethics application status
Approved
Date submitted
24/08/2016
Date registered
1/09/2016
Date last updated
11/10/2021
Date data sharing statement initially provided
26/07/2019
Date results information initially provided
1/12/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Efficacy of umeclidinium bromide and vilanterol (UMEC/VI) for the slowing of chronic obstructive pulmonary disease (COPD) development in smokers
Scientific title
Continuous maximal bronchodilatation with UMEC/VI as first line treatment for smokers at risk of developing COPD
Secondary ID [1] 290002 0
None
Universal Trial Number (UTN)
Trial acronym
The ECOS Study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 300013 0
Condition category
Condition code
Respiratory 299907 299907 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Umeclidinium bromide 62.5mcgs with vilanterol 25 mcgs (Anoro) via Ellipta (inhalation), once daily for 12 months. Adherence will be monitored by empty drug returns.
Intervention code [1] 295710 0
Treatment: Drugs
Comparator / control treatment
Matched placebo via Ellipta, once daily for 12 months. The placebo is a white free flowing powder composed of lactose monohydrate blended with magnesium stearate to match the umeclidinium inhalation powder.
Control group
Placebo

Outcomes
Primary outcome [1] 299390 0
FEV1 (post-bronchodilator) change (mls) from baseline to month 6 after randomisation to active or placebo inhaled medication
Timepoint [1] 299390 0
6 months
Secondary outcome [1] 327023 0
Change from baseline to 6 and 12 months in small airway function as measured by forced oscillation technique (FOT)
Timepoint [1] 327023 0
Visits are conducted at 0, 6 and 12 months.
Secondary outcome [2] 327112 0
Change from baseline to 6 and 12 months in lung volume as measured by assessing lung diffusing capacity for carbon monoxide (DLCO)
Timepoint [2] 327112 0
Visits are conducted at 0, 6, and 12 months.
Secondary outcome [3] 327113 0
To assess the effect of bronchodilators on symptoms using the breathlessness, cough, and sputum scale (BCSS) at 6 and 12 months
Timepoint [3] 327113 0
Visits are conducted at 0, 6, and 12 months.
Secondary outcome [4] 327114 0
To assess differences in reported adverse events between the intervention and placebo treatment groups over 12 months of treatment. Only information on the following adverse events will be collected by medical examination or participant self-report: dry mouth, visual difficulty/blurred vision, palpitations and cardiac events, tremor, pneumonia and upper respiratory tract infections, urinary symptoms or allergic reactions.
Timepoint [4] 327114 0
Visits are conducted at 0, 6 and 12 months.
Secondary outcome [5] 401770 0
Rate of decline of post-bronchodilator FEV1 (expressed as mls/year) following a 12-month intervention on active versus placebo inhaler
Timepoint [5] 401770 0
12 months
Secondary outcome [6] 401771 0
Change in % predicted FEV1 (calculated at post bronchodilator) at 6 and 12 months
Timepoint [6] 401771 0
6 and 12 months
Secondary outcome [7] 401772 0
Change in pre and post bronchodilator FEV1 (L) at 6 and 12 months
Timepoint [7] 401772 0
6 and 12 months
Secondary outcome [8] 401773 0
Change from baseline to 6 and 12 months in lung volume as measured by assessing Lung Diffusing Capacity adjusted for alveolar volume (KCO)
Timepoint [8] 401773 0
6 and 12 months
Secondary outcome [9] 401774 0
Change in pre and post bronchodilator FEV1/FVC at 6 and 12 months
Timepoint [9] 401774 0
0, 6 and 12 months

Eligibility
Key inclusion criteria
1. Aged 25-55 years
2. Current and continuing smoker
3. History of greater or equal to 10 pack years tobacco exposure
4. Normal post-bronchodilator spirometry (FEV1>80% pred, FEV1/FVC>70%) or GOLD Stage 1 (FEV1>80% pred, FEV1/FVC<70%)
5. Abnormal multiple breath nitrogen washout (MBNW) (Sacin, Scond or both derived from MBNW)
6. Willingness and ability to give written informed consent
Minimum age
25 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Unable to perform the tests
2. Have had lung surgery
3.Currently have asthma, defined as a doctor diagnosis of asthma and current symptoms i.e. within 12 months prior to screening
4. Regularly used respiratory preventer/controller medication in the past 5 years
5. Have required frequent use of bronchodilator in the last 5 years (on average>once/week)
6. Have bronchiectasis
7. Have had heart failure
8. Have uncontrolled/unstable arrhythmia
9. Have an upper or lower respiratory tract infection within 6 weeks of screening
10. Cease smoking at the time of the smoking cessation intervention
11. Taking any respiratory medications or other regular medications that could affect respiratory function
12. Regularly smoke tetrahydrocannabinol (THC) > once/week
13. Considered unlikely to be able to adhere to taking study medication over the full 12 months of the treatment period

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The allocation sequence will be by sequentially numbered, opaque, sealed envelopes and will be generated by the data management team at The George Institute for Global Health
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Patients will be allocated to treatment (placebo or active study drug) using computer-generated random numbers. There will be no stratification.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Participant recruitment difficulties
Date of first participant enrolment
Anticipated
5/09/2016
Actual
19/12/2016
Date of last participant enrolment
Anticipated
31/12/2019
Actual
4/02/2020
Date of last data collection
Anticipated
31/01/2021
Actual
28/01/2021
Sample size
Target
320
Accrual to date
Final
65
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 6539 0
Concord Repatriation Hospital - Concord
Recruitment hospital [2] 6540 0
Campbelltown Hospital - Campbelltown
Recruitment hospital [3] 6591 0
Woolcock Institute of Medical Research - Glebe
Recruitment hospital [4] 9915 0
Blacktown Hospital - Blacktown
Recruitment hospital [5] 18131 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 14120 0
2139 - Concord
Recruitment postcode(s) [2] 14121 0
2560 - Campbelltown
Recruitment postcode(s) [3] 14198 0
2037 - Glebe
Recruitment postcode(s) [4] 18724 0
2148 - Blacktown
Recruitment postcode(s) [5] 32124 0
2065 - St Leonards

Funding & Sponsors
Funding source category [1] 294375 0
Commercial sector/Industry
Name [1] 294375 0
GlaxoSmithKline
Country [1] 294375 0
Australia
Primary sponsor type
Other Collaborative groups
Name
The George Institute for Global Health
Address
Level 5
1 King Street
Newtown
NSW 2042
Australia
Country
Australia
Secondary sponsor category [1] 293219 0
None
Name [1] 293219 0
Address [1] 293219 0
Country [1] 293219 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295794 0
Northern Sydney Local Health District
Ethics committee address [1] 295794 0
Research Office
Kolling Building, Level 13
Royal North Shore Hospital
Reserve Road
St Leonards
NSW 2065
Ethics committee country [1] 295794 0
Australia
Date submitted for ethics approval [1] 295794 0
30/11/2015
Approval date [1] 295794 0
14/03/2016
Ethics approval number [1] 295794 0
HREC/15/HAWKE/489

Summary
Brief summary
Cigarette smoking produces inflammation in small airways and development of emphysema in about 20-40% of susceptible individuals. The presence of small airway pathology leads to uneven distribution of ventilation in the lungs as well as excessive airway closure which may produce excessive biomechanical stress leading to further progression of pathology. These changes produce a greater than the normal age-related rate of decline of lung function as measured by the FEV1 and this can lead to the clinical features of COPD. We hypothesise that:
1. The early pathological changes can be identified by tests derived from the multiple breath nitrogen washout (MBNW) and these tests may identify individuals at risk of developing COPD.
2. Bronchodilatation will reduce airway closure and normalise the distribution of ventilation thereby reducing biomechanical stress and may thus lead to reduction in the rate of decline of lung function.
The primary objective is to asses the rate of decline of FEV1 during and at the end of a 12 month intervention with or without active study treatment.
The secondary objective is to assess the change from baseline in small airway function and ventilation heterogeneity, change in FOT, and the effect of bronchodilators on spirometry, DLCO and BCSS symptoms.
The study is a double-blind, placebo controlled, parallel design study comparing:
1. Umeclidinium bromide with vilanterol (Anoro) via the Ellipta dry powder inhalation device at a dose of 62.5mcg/25mcg once daily with
2. Matched placebo once daily
A total of 100 participants will be randomised from four centres in NSW, Australia. Subject will attend clinic visits at screening, randomisation, 26 weeks and 52 weeks. Monthly telephone calls will be made to each participant to record adverse events, concomitant medications, adherence to medication and current smoking status.
Study measurements will include spirometry pre and post bronchodilator, body plethysmography to measure lung volumes and DLCO, MBNW, FOT and BCSS symptoms.

The student t-test will be used to compare the annual rate of decline of the FEV1 between the active treatment and placebo groups. Statistical methods for analysing the secondary outcomes will be by a linear regression model adjusted for baseline measurements if applicable
Trial website
https://woolcock.org.au/ecos/
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 68498 0
Prof Christine Jenkins
Address 68498 0
The George Institute for Global Health
Level 5, 1 King Street
Newtown NSW 2042 Australia
Country 68498 0
Australia
Phone 68498 0
+61 2 8052 4300
Fax 68498 0
Email 68498 0
[email protected]
Contact person for public queries
Name 68499 0
Ms Tanya Badal
Address 68499 0
Woolcock Institute of Medical Research
The University of Sydney
431 Glebe Point Road
Glebe
NSW2037
Country 68499 0
Australia
Phone 68499 0
+61 2 9114 0400
Fax 68499 0
Email 68499 0
[email protected]
Contact person for scientific queries
Name 68500 0
Prof Christine Jenkins
Address 68500 0
The George Institute for Global Health
Level 5, 1 King Street
Newtown NSW 2042 Australia
Country 68500 0
Australia
Phone 68500 0
+61 2 8052 4300
Fax 68500 0
Email 68500 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
To retain participant privacy we only obtain de-identified information in our CRF. The data published at the end of the study will not be individual data, only summary intervention/placebo data.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe effect of oxygen and carbon dioxide cross-sensitivity sensor error in the Eco Medics Exhalyzer D device on measures of conductive and acinar airway function.2022https://dx.doi.org/10.1183/23120541.00614-2021
N.B. These documents automatically identified may not have been verified by the study sponsor.